FDA launches new market pathway for breakthrough medical devices

This article was originally published here
Share

Emergo GroupBy Stewart Eisenhart, Emergo Group

The US Food and Drug Administration plans to establish a new market authorization pathway for innovative and breakthrough medical devices that would replace current priority review programs including the Expedited Access Pathway (EAP) and the Priority Review Program.

Get the full story here at the Emergo Group’s blog.

The opinions expressed in this blog post are the author’s only and do not necessarily reflect those of MassDevice.com or its employees.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply